You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

100 search results for: mechanism of disease

Neuroimmune Axis and Neuroinflammation in PN
expert video

Neuroimmune Axis and Neuroinflammation in PN

Dermatology
A review of the neuroimmune mechanisms and changes to the dermis that result in itch in PN.
View more
Mast Cells and the Neuroimmune Axis in CSU
expert video

Mast Cells and the Neuroimmune Axis in CSU

Dermatology
A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
ADVENT On Air | Exploring PN as a Distinct and Unique <b>Disease</b>
Podcast

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

Dermatology
Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.
View more
<b>Disease</b>-Specific Aspects <b>of</b> Itch in AD, PN, and CSU
expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

Dermatology
Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.
View more
Atopic Dermatitis and Prurigo Nodularis: Distinct skin <b>disease</b>s with shared characteristics
Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

Dermatology
An infographic exploring the shared and distinct clinical characteristics of atopic dermatitis and prurigo nodularis.
View more
Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct <b>Disease</b>s with Shared Characteristics
interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

Dermatology
Explore our interactive tool showcasing the unique and shared features, burden, and risk factors of atopic dermatitis and prurigo nodularis.
View more
ERS 2024 | A Breath <b>of</b> Fresh Air: A Greater Understanding <b>of</b> COPD With Type 2 Inflammation
expert video

ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

Pulmonology
Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies
View more
Describing <b>Disease</b> Control in PN
expert video

Describing Disease Control in PN

Dermatology
Dr. Chovatiya discusses PN, emphasizing that while itch is a major symptom, the disease's burden is multi-dimensional, affecting appearance, sleep, social life, and mental health, requiring comprehensive therapeutic solutions.
View more
PN is Considered a Unique Clinical Entity Distinct from Other Pruritic <b>Disease</b>s and Psychiatric Conditions
expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

Dermatology
Dr. Sarina Elmariah discusses PN being a unique clinical entity, distinct from other pruritic diseases and psychiatric conditions.
View more
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Dermatology
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
View more
The Potential Impact <b>of</b> Early Intervention in Atopic Dermatitis in Children
expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

Dermatology
Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BelgiumChange country/region